Hello! This is Michelle, WCL’s registered dietitian, with this month’s Nutrition Minute because we want to MAKE EVERY MINUTE COUNT.
Resources & Latest News
By CHARLES E. DRISCOLL, MD
Aducanumab (Aduhelm, Biogen) was fast-tracked through the FDA in June of 2021 receiving accelerated approval to treat mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD). People with more advanced stages of AD are not candidates for the drug although the FDA did not specify who should not receive it.
Westminster at Home is proud to have been a part of the latest issue of Lynchburg Living.